Layne S P, Merges M J, Spouge J L, Dembo M, Nara P L
Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, New Mexico 87545.
J Virol. 1991 Jun;65(6):3293-300. doi: 10.1128/JVI.65.6.3293-3300.1991.
Quantitative infectivity assays were used to study how the blocking activity of soluble CD4 (sCD4) is affected by sCD4 concentration, target cell density, and viral stock age. During incubation with 20 nM sCD4, human immunodeficiency virus type 1 (HIV-1) stocks underwent irreversible inactivation. In contrast, inactivation with 2 nM sCD4 was almost entirely reversible. At lower sCD4 concentrations (less than or equal to 2 nM) and target cell densities of 6.25 x 10(4) ml-1, sCD4 blocking activity for HIV-1 gave a gp120-sCD4 association constant (Kassoc) of 1.7 x 10(9) M-1, which agrees with chemical measurements. At the higher density of 1.6 x 10(7) cells ml-1, however, the blocking activity was 20-fold less. During incubation of HIV-1 stock optimized for infectivity by rapid harvest, sCD4 blocking activity increased 20-fold during a 3-h window. These results show that competitive blocking activity depends strongly on target cell density and virion age. Thus, unappreciated variations in HIV stocks and assay conditions may hinder comparisons of blockers from laboratory to laboratory, and the age of HIV challenge stocks may influence studies of drug and vaccine efficacy. The results also suggest that blocking of viral particles in lymphoid compartments will require very high competitive blocker concentrations, which may explain the refractory outcomes from sCD4-based drug trials in humans.
采用定量感染性测定法来研究可溶性CD4(sCD4)的阻断活性如何受到sCD4浓度、靶细胞密度和病毒储备液保存时间的影响。在与20 nM sCD4孵育期间,1型人类免疫缺陷病毒(HIV-1)储备液发生了不可逆的失活。相比之下,用2 nM sCD4进行的失活几乎完全是可逆的。在较低的sCD4浓度(小于或等于2 nM)和6.25×10⁴ ml⁻¹的靶细胞密度下,sCD4对HIV-1的阻断活性得出gp120-sCD4结合常数(Kassoc)为1.7×10⁹ M⁻¹,这与化学测量结果一致。然而,在1.6×10⁷个细胞/ml的较高密度下,阻断活性降低了20倍。在通过快速收获优化感染性的HIV-1储备液孵育期间,sCD4阻断活性在3小时的时间段内增加了20倍。这些结果表明,竞争性阻断活性强烈依赖于靶细胞密度和病毒粒子的保存时间。因此,HIV储备液和测定条件中未被重视的差异可能会阻碍不同实验室之间对阻断剂的比较,并且HIV攻击储备液的保存时间可能会影响药物和疫苗疗效的研究。结果还表明,在淋巴组织区室中阻断病毒颗粒将需要非常高的竞争性阻断剂浓度,这可能解释了基于sCD4的人体药物试验的难治性结果。